Former Ergomed CEO appointed as Midatech’s Chief Financial Officer

pharmafile | September 11, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ergomed, midatech 

Immunotherapy-focused pharmaceutical company Midatech Pharma has appointed Stephen Stamp as Chief Financial Officer (CFO) with immediate effect.

He will be replacing Nick Robbins-Cherry, who has stepped down after five years since joining in 2014. Robbins will nevertheless remain at Midatech until October to facilitate Stamp’s handover in an orderly fashion.

Stamp has most recently served as CEO of pharmaceutical firm Ergomed for two years, stepping down in January citing health reasons. Prior to this he was CFO at Ergomed for a year beginning in 2016.

Stamp has also served as CFO of US-based personalised medicine group AssureRx Health for three years between 2013 and 2016.

Chair Rolf Stahel said on Stamp’s appointment: “The directors are delighted to welcome Stephen Stamp to the board of Midatech as CFO.

“He brings a wealth of relevant financial, commercial and industry experience gained in a wide range of senior roles at major healthcare companies, in the UK and internationally, which will enable him to make a significant contribution to Midatech’s future success. This is an exciting time for the company and having someone of Stephen’s financial pedigree joining will be a real asset.”

Related Content


EUSA Pharma’s COVID-19 drug improves or stabilises respiratory condition in 76% of patients

EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the …


EUSA Pharma and Ergomed partner to investigate IL-6 targeting in COVID-19 patients with serious respiratory complications

Oncology and rare disease firm EUSA Pharma is aiding in the global fight against the …


Midatech launch treatment to reduce chemo-induced vomiting in the US

Midatech Pharma (NASDAQ: MTP) has the full commercial launch of Zuplenz (ondansetron) in the US. …

Latest content